A groundbreaking study originating from Stanford Medicine and its collaborative partners has unveiled a critical and previously underappreciated health disparity: individuals living with color vision deficiency (CVD) face a significantly heightened mortality rate when diagnosed with bladder cancer. This comprehensive research, leveraging vast repositories of patient data, suggests that the inability to discern certain color tones, particularly red, can obscure the earliest and often most crucial warning sign of the disease—the presence of blood in urine—leading to delayed diagnoses and ultimately, a poorer prognosis.
The core finding of the investigation, published in the esteemed journal Nature Health, indicates a stark reality: bladder cancer patients who also possess color vision deficiency experienced a 52% higher risk of mortality over a two-decade period compared to their counterparts with normal color perception. This substantial difference underscores a profound clinical implication, spotlighting the need for increased awareness among both the public and medical professionals regarding the subtle ways a common visual impairment can intersect with a serious malignancy. Dr. Ehsan Rahimy, an adjunct clinical associate professor of ophthalmology and the senior author of the study, expressed optimism that these findings would serve to educate both patients and the medical community who provide their care. The lead authorship was attributed to Mustafa Fattah, a medical student affiliated with Columbia University Vagelos College of Physicians and Surgeons.
Color vision deficiency, commonly referred to as colorblindness, is a widespread genetic condition, affecting approximately one in every twelve men and one in every two hundred women. The most prevalent forms primarily impact the ability to differentiate between red and green hues. This impairment can manifest in various daily challenges, ranging from interpreting traffic signals and selecting coordinated attire to assessing the doneness of cooked meat. Critically, for medical purposes, it can impede the recognition of sanguineous indicators in bodily fluids. Many individuals with CVD may not even be aware of their condition, as it often presents without other visual impairments and can be navigated through compensatory strategies in daily life. This lack of formal diagnosis further complicates its consideration within healthcare contexts.
Bladder cancer, a malignancy predominantly affecting the urinary bladder, also exhibits a higher incidence in men, who are approximately four times more likely to develop the disease than women. Projections for the year 2025 anticipated around 85,000 new diagnoses of bladder cancer in the United States alone. A distinguishing characteristic of bladder cancer is its frequent initial presentation: between 80% and 90% of patients first report painless hematuria, or the visible presence of blood in their urine. This symptom typically serves as a critical prompt for medical evaluation, facilitating an early diagnosis when therapeutic interventions are most effective and survival rates are considerably higher. However, for those with impaired red perception, this vital visual cue can go unnoticed, postponing the critical window for intervention.
The current large-scale study was not without its precedents. Earlier, smaller-scale investigations and anecdotal reports had hinted at a potential link between color vision deficits and delayed detection of various diseases, particularly those where blood in excretions served as an early warning. For instance, a study conducted in 2009 involving 200 male bladder cancer patients found that individuals with impaired color vision were often diagnosed at more advanced, invasive stages of the disease compared to those with unimpaired vision. Further emphasizing this point, an experimental setup in 2001 challenged participants to identify blood within samples of saliva, urine, and stool. While participants with typical color perception achieved a 99% accuracy rate, those with color vision deficiency correctly identified the samples only 70% of the time, starkly illustrating the diagnostic challenge. These foundational observations provided the impetus for Dr. Rahimy and his team to undertake a more expansive inquiry into whether CVD ultimately impacted long-term survival outcomes for patients with bladder or colorectal cancers.
To meticulously explore this hypothesis, the researchers harnessed the immense capabilities of TriNetX, a sophisticated global research platform that aggregates real-time electronic health records (EHRs). This colossal database, encompassing approximately 275 million de-identified patient records, offers an unparalleled resource for epidemiological studies. The sheer volume of data within such a system allows researchers to pinpoint highly specific patient cohorts, identifying individuals who share an unusual combination of medical conditions, a task nearly impossible with smaller datasets. As Dr. Rahimy articulated, the strength of this research methodology lies in its capacity to curate a specific population of interest, such as patients with both colorblindness and bladder cancer—a combination that might be rare in isolation but becomes detectable when sifting through an ocean of patient information.
From a subset of roughly 100 million U.S. patient records, the research team successfully identified 135 individuals diagnosed with both color vision deficiency and bladder cancer. Additionally, they identified 187 patients presenting with both colorblindness and colorectal cancer. For each of these distinct groups, a meticulously matched control group was established. These control patients shared the same cancer diagnosis and comparable demographic and health characteristics but possessed normal color vision, ensuring a robust and statistically sound comparison of outcomes.
The analysis of the bladder cancer cohort yielded compelling results, affirming the initial hypothesis. Patients with color vision deficiency exhibited a markedly reduced likelihood of survival compared to those with normal vision. Over a twenty-year observational period, the aggregate mortality risk for the colorblind group was found to be 52% higher. This comprehensive mortality risk encompassed deaths from all causes, not exclusively bladder cancer-related fatalities, suggesting a broad impact stemming from the initial delayed diagnosis.
Intriguingly, the researchers had initially anticipated a similar pattern of increased mortality among individuals with colorectal cancer and color vision deficiency. However, their analysis revealed no statistically significant difference in survival rates between colorectal cancer patients with and without CVD. This divergence in findings can be attributed to several key distinctions in the typical presentation and screening protocols for colorectal cancer. Unlike bladder cancer, where painless hematuria is the predominant initial symptom, colorectal cancer often manifests with a broader spectrum of early indicators. Dr. Rahimy highlighted that the presence of blood in stool is frequently not the primary or most common symptom reported by these patients. Studies indicate that nearly two-thirds of colorectal cancer patients initially experience abdominal pain, while over half notice changes in their bowel habits. Furthermore, the widespread recommendation for routine colorectal cancer screening for individuals between the ages of 45 and 75 significantly reduces reliance on patients noticing blood in their stool as the first alarm bell, thereby mitigating the potential impact of color vision deficiency on diagnostic timeliness for this particular malignancy.
The researchers also issued a crucial caveat regarding their findings, suggesting that the observed mortality difference might, in fact, be underestimated. The study’s reliance on standard diagnostic codes, specifically ICD-10 codes recorded within electronic health records, presents a limitation. A substantial number of individuals with color vision deficiency never receive a formal medical diagnosis, meaning they would be categorized as having normal vision within the database. This misclassification implies that the true cohort of bladder cancer patients with undiagnosed CVD could be larger, potentially masking an even greater disparity in survival outcomes than what was observed in the formally identified groups. As Dr. Rahimy noted, many individuals with CVD function perfectly well and may not even be aware of their condition, further obscuring its prevalence in medical records.
The profound implications of these findings underscore an urgent need for additional research to thoroughly elucidate how color vision impairment influences the detection and progression of various diseases. This "30,000-foot view," as Dr. Rahimy described it, points to specific trends that warrant more granular and in-depth analyses. Importantly, the study has already initiated vital dialogues within the medical community. Dr. Rahimy reported that conversations with urologists and gastroenterologists, including one colleague who is colorblind, revealed a prior lack of consideration for color vision deficiency as a factor in cancer diagnosis. Some clinicians have expressed an intent to incorporate questions about colorblindness into their standard screening questionnaires, a simple yet potentially life-saving adjustment.
For individuals living with color vision deficiency, these results powerfully emphasize the critical importance of adhering to routine health examinations. Doctors generally advise annual check-ups that include urine tests. Beyond this, a proactive approach to monitoring personal health is paramount. For those who may harbor doubts about their ability to detect subtle changes in urine color, seeking assistance from a trusted partner or family member for periodic visual checks for blood is a recommended strategy. This collaborative vigilance can serve as an invaluable early warning system.
The study benefited from contributions by a researcher affiliated with Beaumont Health and received financial support from the National Institutes of Health (grant P30-EY026877) and Research to Prevent Blindness, Inc. These findings represent a significant stride in understanding the complex interplay between seemingly disparate health conditions, ultimately paving the way for more inclusive and effective early detection strategies in oncology.
About the Author
